Overall, our findings suggest that XYAS can alleviate psoriasis like-inflammation and abnormal skin morphology in mice with psoriasis complicated by SDs, the pharmacological mechanism of which is possibly related to skin MLT-RORα upregulation, antioxidant activities enhancements, and a suppression of mitochondrial damage. Here, RORA is linked to psoriasis.